Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound
a technology of angiogenesis and composition, which is applied in the direction of drug compositions, biocide, heterocyclic compound active ingredients, etc., can solve the problem of no reports demonstrating the anti-angiogenic activity of the compound, and achieve the effect of improving drug safety and effective use for prevention or treatmen
Inactive Publication Date: 2014-10-09
IND ACADEMIC CORP FOUND YONSEI UNIV
View PDF1 Cites 6 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The present invention provides a pharmaceutical composition that can prevent or treat diseases related to angiogenesis. The composition contains a compound that inhibits the formation of new blood vessels without causing toxicity at low concentrations. This compound inhibits the expression of angiogenic factors like VEGF, which are involved in the process of angiogenesis. The use of this compound improves the safety of the pharmaceutical composition.
Problems solved by technology
However, there have been no reports demonstrating the anti-angiogenic activity of the compound.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
examples
Materials and Methods
[0046]Materials
[0047]Voacangine (12-methoxyibogamine-18-carboxylic acid methyl ester) was purchased from THC Pharm (Frankfurt, Germany). Endothelial growth medium-2 (EGM-2) was purchased from Lonza (Walkersville, Md.). RPMI 1640 and fetal bovine serum (FBS) were purchased from Invitrogen (Grand Island, N.Y.). Vascular endothelial growth factor (VEGF), Matrigel and Transwell chamber systems were obtained from KOMA Biotech (Seoul, Korea), BD Bioscience (Bedford, Mass.) and Corning Costar (Corning, N.Y.), respectively. Anti-HIF-1α, anti-cyclin D1 and anti-tubulin antibody were purchased from BD Bioscience, Cell Signaling (Beverly, Mass.) and Millipore (Billerica, Mass.), respectively.
Cell Culture and Proliferation Assay
[0048]Human umbilical vascular endothelial cells (HUVECs) were grown for 7-11 passages in EGM-2 medium supplemented with 100 FBS. HepG2 (human liver carcinoma) cells were grown in RPMI 1640 containing 10% FBS and 1% antibiotics. All cell lines were m...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| Cell angle | aaaaa | aaaaa |
Login to View More
Abstract
The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.
Description
TECHNICAL FIELD [0001]The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising, as an active ingredient, a plant-derived natural compound having anti-angiogenic activity.DESCRIPTION OF THE RELATED ART [0002]Angiogenesis, the formation of new blood vessels from existing microvessels, is important in embryogenesis, wound healing, and tissue or organ regeneration [1,2]. However, pathological angiogenesis can lead to solid tumor growth and metastasis, diabetic retinopathy, and other diseases [3,4]. Accordingly, the inhibition of angiogenesis is considered a promising strategy for the treatment of cancer and other human diseases linked with angiogenesis [2,5].[0003]Natural compounds have played a positive role in the advancement of new bioactive small molecules as leads for drug development [6]. Some natural compounds act as anti-viral, anti-bacterial, and anti-cancer agents. For instance, etoposide, a topoisomerase inhibitor derived from podop...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/55
CPCA61K31/407A61K31/5517A61K31/55A61P35/00
Inventor KWON, HO JEONGKIM, YONG HYO
Owner IND ACADEMIC CORP FOUND YONSEI UNIV